US EditionJohnson & Johnson medtech highlights clinical evidence for VARIPULSE platform in atrial fibrillation care
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
RHÖN-KLINIKUM AG [Newsroom]Bad Neustadt a.d. Saale (ots) - The team of the Department of Cardiology II at the RHÖN-KLINIKUM Campus Bad Neustadt is one of the first to successfully use the new dual energy THERMOCOOL SMARTTOUCH(TM) SF catheter.This catheter ... Continue reading here...Original content of: RHÖN-KLINIKUM AG, transmitted by news up-to-date
Johnson & Johnson medtech highlights clinical evidence for VARIPULSE platform in atrial fibrillation care
The VARIPULSE Platform includes the VARIPULSE Catheter, TRUPULSE Generator, and CARTO 3 Mapping System VARIPULSE Software. The platform is approved for use in the United States, Europe, Asia Pacific, Canada, and Latin America. More than 25,000 procedures have been performed across the U.S., Europe, Canada, Japan, Hong Kong, Mainland China, Korea, Taiwan, and Australia. Johnson & Johnson MedTech is presenting new clinical and real-world evidence …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
